A single-blind, randomized, controlled, phase II study to evaluate immunogenicity and safety of two doses of the MVA [modified vaccinia Ankara]-Nef HIV vaccine in HIV-1 infected patients with CD4 above 250/microL

Trial Profile

A single-blind, randomized, controlled, phase II study to evaluate immunogenicity and safety of two doses of the MVA [modified vaccinia Ankara]-Nef HIV vaccine in HIV-1 infected patients with CD4 above 250/microL

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs MVA-BN-nef (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 20 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top